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Abstract
Current HIV vaccine approaches are focused on immunogens encoding whole HIV antigenic proteins that mainly elicit
cytotoxic CD8+ responses. Mounting evidence points toward a critical role for CD4+ T cells in the control of
immunodeficiency virus replication, probably due to cognate help. Vaccine-induced CD4+ T cell responses might, therefore,
have a protective effect in HIV replication. In addition, successful vaccines may have to elicit responses to multiple epitopes
in a high proportion of vaccinees, to match the highly variable circulating strains of HIV. Using rational vaccine design, we
developed a DNA vaccine encoding 18 algorithm-selected conserved, ‘‘promiscuous’’ (multiple HLA-DR-binding) B-subtype
HIV CD4 epitopes - previously found to be frequently recognized by HIV-infected patients. We assessed the ability of the
vaccine to induce broad T cell responses in the context of multiple HLA class II molecules using different strains of HLA class
II- transgenic mice (-DR2, -DR4, -DQ6 and -DQ8). Mice displayed CD4+ and CD8+ T cell responses of significant breadth and
magnitude, and 16 out of the 18 encoded epitopes were recognized. By virtue of inducing broad responses against
conserved CD4+ T cell epitopes that can be recognized in the context of widely diverse, common HLA class II alleles, this
vaccine concept may cope both with HIV genetic variability and increased population coverage. The vaccine may thus be a
source of cognate help for HIV-specific CD8+ T cells elicited by conventional immunogens, in a wide proportion of
vaccinees.
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Introduction
Given the proportions of the AIDS pandemic, development of
an effective vaccine against human immunodeficiency virus type 1
(HIV-1) remains one of the most important biomedical research
priorities. Only three vaccine concepts have completed clinical
efficacy studies so far, with two negative results (Env gp 120
vaccine -AIDSVAX; recombinant Adenovirus 5 HIV-1 gag/pol/
nef trivalent vaccine -STEP trial [1]), and one showing borderline
efficacy, with no effect on HIV-1 viral load (recombinant
canarypox ALVAC (gp120/Gag/Protease) prime - gp120 protein
boost - ALVAC-AIDSVAX) [2].
Vaccination regimens that induced cell-mediated immunity
were shown to significantly reduce simian immunodeficiency virus
(SIV) replication in non-human primates [3], [4], [5]. Therefore,
most of the HIV-1 vaccine field is currently focused on
development of vaccines that elicit potent cytotoxic CD8+
responses. The lack of efficacy of the recently studied STEP trial
of the Adenovirus 5 HIV-1 gag/pol/nef trivalent vaccine [6]
may have been related to the narrowness of the induced T
cell response – on average, only one epitope was recognized per
HIV-1 gene product in each vaccinee [7]. Recent evidence from
the SIV infected macaque model show that heterozygote animals,
which carry more MHC molecules and present a broader T cell
response, display better control of viral load than their
homozygote counterparts [8]. It has thus been argued that the
development of novel vaccine strategies that elicit a greater epitope
breadth, matching T cell responses to circulating HIV strains, is a
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variable HIV-1 [7]. In addition, 30% and 60% of vaccinees in the
STEP trial failed to display CD8+ and CD4+ T cell responses to
HIV epitopes, respectively [9]. Regarding the ALVAC-AIDSVAX
trial, no CD8+ T cell responses were detected among the
vaccinees, and 66% of them failed to display CD4+ T cell
responses to gp120 [2]. Thus, vaccines tested in recent efficacy
trials failed to induce CD8+ and especially CD4+ T cell responses
in a significant proportion of vaccinees. The lack of population
coverage may thus have been another cause of the insufficient
results of the trials. Thus, innovative vaccine antigen design and
immunogen formulation is needed in order to develop a vaccine
able to induce broad immune responses in the majority of
vaccinees. One possible way to increase the breadth of the
response would be to include most or all of the HIV-1 proteome
into a viral vector [5]. However, most viral vectors pose constraints
on insert size, and developing such a vaccine for large-scale use
could be technically challenging or impractical. On the other
hand, epitope-based vaccines combine multiple T cell epitopes
assembled in tandem, and can focus the immune response on any
chosen group of epitopes (e. g. conserved and highly antigenic),
generating much smaller insert sizes. Every single epitope can be
immunogenic in multiple epitope-based vaccines; in addition, they
have been reported to generate broad and potent immune
responses [10], [11], [12], [13], [14]. By eliminating epitope
flanking regions, epitope vaccines are also devoid of mutations that
impair antigen processing and presentation, which may have
accumulated in the flanking regions along viral evolution [15].
In spite of the abundant evidence that cytotoxic CD8+ T
lymphocytes are the primary anti-HIV-1 effectors [16], several
studies have shown that a strong specific CD4+ T-cell response is
associated with control of viral replication and long-term
nonprogression to AIDS [17], [18], [19], [20]. It has been shown
that specific CD4+ T cells play a major role in the generation of a
CD8+ cytotoxic T cell response and neutralizing antibodies, able
to control viral replication [21], [22], [23]. Furthermore, CD4+ T
cells contribute to T cell vaccine-induced protection in SIV-
infected primates [24], [25]. Protective mechanisms include
cognate help for functional CD8+ T cell memory [26], [27],
mobilization of effector CD8+ T cells to peripheral sites of
infection [28], and inhibition of SIV replication in infected
macrophages [29]. In addition, virus-specific CD4+ T cells may be
able to tolerate more sequence diversity in their target epitopes
than CD8+ T cells, therefore being more resistant to mutational
escape [30]. It follows that deliberate inclusion of HIV-1 CD4+ T
cell epitopes in HIV-1 immunogens, to provide cognate help and
boost CD8+ T cell responses, might be a desirable approach for
prophylactic T cell vaccines.
With the aid of the TEPITOPE algorithm [31], our group has
previously identified a set of 18 conserved CD4+ T-cell epitopes,
derived from HIV-1 subtype B consensus whole proteome,
capable of binding to multiple HLA-DR molecules [32]. The 18
peptides were recognized, and PBMC (peripheral blood mononu-
clear cells) from over 90% of HIV-1-infected patients displayed
IFN-c ELISPOT responses to the peptides; each patient
recognized on average 5 peptides, including both CD4+ and
CD8+ T cell responses [32]. A vaccine encoding multiple
conserved epitopes may increase crossreactivity between different
HIV strains, possibly circumventing HIV-1 genetic variability [1].
Furthermore, one would expect that a vaccine built with multiple
‘‘promiscuous’’ peptides, capable to bind to several HLA class II
molecules could lead to an increased coverage of the genetically
heterozygous human population. Since essentially all HLA class II
molecules tested were shown to bind to multiple promiscuous
HIV-1 epitopes [32], it is expected that most individuals could
develop broad T cell responses. We thus hypothesized that an
immunogen containing such a set of 18 conserved, highly
promiscuous, immunodominant epitopes from 8 different HIV-1
proteins could potentially elicit a broad T cell response in a high
proportion of individuals bearing distinct HLA class II molecules.
In order to test our hypothesis, we designed a DNA vaccine
encoding the 18 described HIV-1 epitopes. To assess its
immunogenicity, we used four mouse strains transgenic to
common HLA class II molecules (HLA-DR2, -DR4, -DQ6, -
DQ8 present in 35–50% of the population), as a preclinical rodent
model of the HLA class II diversity found in humans [33], [34],
[35]. It has been reported that HLA class II-transgenic mice are
able to develop CD4+ T cell responses to the same HLA-restricted
epitopes recognized by humans carrying the same HLA class II
molecule [36], [37]. Broad T cell responses were observed in all
strains, covering 16 out of the 18 epitopes encoded by the DNA
vaccine. We observed multiple CD4+ T cell responses restricted
by several HLA-DR and –HLA-DQ molecules, as well as CD8+ T
cell responses restricted to murine class I MHC. We believe this
vaccine design may be potentially useful as a source of cognate T
cell help to CD8+ T cell responses in novel HIV-1 vaccine
candidates.
Results
The HIVBr18 vaccine is immunogenic and induces
significant HIV-specific cytokine and proliferative T cell
responses in HLA class II transgenic strains of mice
To assess the magnitude and coverage of the peptide-specific
response induced by the HIVBr18 vaccine in mouse strains
transgenic to HLA-DR2, -DR4, -DQ6 and –DQ8, we analyzed T
cell proliferation and cytokine production against pooled HIV-1
peptides. Using the CFSE (carboxyfluorescein diacetate succini-
midyl ester, Molecular Probes) - based proliferation assay, we
observed significant peptide-specific proliferation of both CD4+
and CD8+ splenic T cells derived from HIVBr18-immunized
mice. Figure 1 depicts a representative experiment, using the
DR4-transgenic strain. All four HLA class II-transgenic strains of
mice presented positive proliferative responses against pooled
HIV-1 peptides in splenic CD4+ T cells (Figure 2A), while strong
specific CD8+ T cell responses were essentially detected only in -
DR2- and DR4-Tg mice (Figure 2B). Mice from all four HLA
class II-transgenic strains were able to secrete IFN-c against
pooled HIV-1 peptides as measured by ELISPOT (Figure 2C). In
contrast, splenocytes from mice immunized with pVAX1 present-
ed negligible numbers of IFN-c secreting cells.
Broad specific CD4+ and CD8+ T cell responses following
immunization HIVBr18 in HLA class II transgenic mice
To determine whether this vaccine concept would be able to
induce a broad specific immune response, splenocytes from
immunized mice were incubated with each of the 18 individual
HIV-1 peptides encoded by the DNA vaccine (Table S1).
Immunization with HIVBr18 elicited significant numbers of
IFN-c secreting cells directed to different vaccine-encoded
epitopes in HLA-DR2, -DR4, -DQ6 and -DQ8 transgenic mice,
which recognized 5, 4, 10 and 1 peptides, respectively (Figures 3
A, B, C and D, respectively). Of note, the epitope p17 (73–89)
induced IFN-c secretion by spleen cells from all transgenic strains.
We also evaluated the proliferative T cell responses of immunized
HLA class II transgenic mice against the 18 individual peptides.
Splenocytes from immunized HLA-DR2, -DR4, -DQ6 and -DQ8
transgenic mice also displayed CD4+ T cell responses to different
CD4 Epitope-Based HIV Vaccine
PLoS ONE | www.plosone.org 2 June 2010 | Volume 5 | Issue 6 | e11072vaccine-encoded epitopes (1, 6, 11 and 0 peptides were
recognized, respectively) (Table 1). Several such responses were
shared between different HLA class II-transgenic mouse strains.
CD8+ T cell responses, on the other hand, were less frequent
among immunized HLA-DR2, -DR4, -DQ6 and DQ8 transgenic
mice (4, 2, 0 and 1 peptides, respectively) (Table 2). Taken
together, HLA class II transgenic mice displayed CD4+ and CD8+
T cell responses to 11 and 6 epitopes, respectively.
In summary, immunization with HIVBr18 was able to induce
multiple T cell responses in all 4 HLA class II-transgenic mouse
strains tested, against 16 out of the 18 epitopes encoded by the
vaccine (Figure 4). Significantly, 11 peptides were recognized by
proliferating CD4+ T cells, some of them being recognized by
several HLA class II transgenic strains of mice.
Discussion
In this report, we have developed a DNA vaccine encoding 18
conserved, multiple HLA-DR-binding HIV-1 CD4+ T cell
epitopes frequently recognized by HIV-1-infected patients. The
HIVBr18 vaccine was immunogenic in four mouse strains
transgenic to the common HLA class II molecules HLA-DR2, -
DR4, -DQ6 and -DQ8. Moreover, vaccination with HIVBr18
induced broad MHC class II-restricted T cell responses in the
HLA class II-transgenic strains of mice, and 16 out of the 18
encoded epitopes could be recognized. Indeed, recent clinical trials
of T cell-based HIV vaccines [9] strongly suggested that induction
of broad immune responses towards conserved epitopes, in the
majority of the genetically heterogeneous vaccinees, may be an
essential pre-requisite for novel vaccine candidates [38], [39].
Vaccination of non-human primates with an Adenovirus 5 vaccine
encoding 8 SIV proteins and devoid of Env caused a significant
reduction in viral load after heterologous challenge [5], and
induced broad CD4+ and CD8+ T cell responses. The breadth of
pre-challenge SIV-specific T-cell responses correlated with lower
viral loads and higher CD4+ lymphocyte counts [40].
An effective T cell vaccine should also have significant
population coverage, given the extensive HLA polymorphism
Figure 1. Immunization with HIVBr18 induces significant CD4+ and CD8+ T cell proliferation against pooled HIV peptides. Two
weeks after the last last immunization with HIVBr18, spleen cells from a HLA-DR4 mouse were labeled with CFSE (1.25 mM) and cultured for 5 days in
the presence of 5 mM of 18 pooled HIV-1 peptides. Cells were analyzed by flow cytometry and CFSE
low cells on gated CD3+CD4+or CD3+CD8+ was
used as a readout for antigen-specific proliferation. Representative dot plots of CD4+ (left) and CD8+ (right) T cell proliferation (%CFSElow cells) of
splenocytes stimulated with medium or pooled peptides from HIVBr18 immunized mice.
doi:10.1371/journal.pone.0011072.g001
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way to ensure maximum coverage is to include multiple epitopes
where each one could bind to multiple HLA molecules. The
TEPITOPE prediction algorithm has been successfully applied to
the identification of multiple HLA-DR-binding, ‘‘promiscuous’’ T
cell epitopes in the context of several human infectious, allergic
and autoimmune diseases [41], [42], [43], [44]. A significant
correlation was observed between the TEPITOPE-predicted
promiscuity (ie the number of HLA-DR molecules predicted to
bind to a certain peptide) and the number of HLA-DR molecules
that could actually bind the peptide in biochemical assays [45]. In
the conserved HIV-1 peptide set identified by our group and
encoded by the HIVBr18 vaccine, each peptide could bind on
average to 50% of the 9 common HLA-DR specificities tested.
Conversely, most HLA-DR molecules bound to at least 10 of the
peptides, indicating that an individual bearing at least one such
HLA-DR molecule could develop broad CD4+ T cell responses
against the HIV-1 peptide set [32]. Concerning the 6 peptides that
elicited IFN- c secretion or CD4+ T cell proliferative responses in
HLA-DR2 (DRB1*1501) transgenic mice, we observed that all of
them were also recognized by one or more of the 5 HLA-matched
HIV-1-infected individuals tested; all 6 peptides presented binding
capacity to the HLA DRB1*1501 molecule (data not shown [32])
(Table S2). Regarding the 7 peptides that elicited IFN-c secretion
or CD4+ T cell proliferative responses in HLA-DR4 transgenic
mice, we observed that 3 were also recognized by the single HLA-
DR4 HIV-1-infected individual tested [32] (Table S3).
The promiscuity of HLA class II binding of TEPITOPE-
selected peptides may extend beyond the limited number of
molecules in the prediction matrix. This is suggested by the cross-
species recognition of TEPITOPE-selected peptides [45], indicat-
ing that the algorithm may select for peptides that share MHC
class II binding motifs similar to many other human and non-
human MHC class II molecules [31]. This may explain why so
many HIV-1 infected patients and, in the present case, mice
transgenic to HLA-DQ6 and -DQ8, HLA class II alleles whose
binding is not predicted by the TEPITOPE algorithm, also
displayed broad T cell responses to the selected HIV-1 peptide set.
In addition, all TEPITOPE-selected HIV-1 peptides were
predicted to bind to H-2
d class II molecules, and immunization
of BALB/c (H-2
d) mice with HIVBr18 also induced broad specific
T cell responses to predicted peptides (unpublished observations).
The fact that each HLA class II transgenic strain recognized a
different set of CD4 epitopes after immunization with HIVBr18 is
in line with MHC class II-restricted recognition. Further in
support of this, the fact that all peptides recognized by HLA-
DR2(DRB1*1501)-transgenic mice were also recognized by at
least one of the 5 tested HLA-DR15 HIV-1 infected patients [32]
indicates that findings in HLA class II-transgenic mice accurately
translates human responses (Table S2). The recognition of
additional epitopes by some patients could possibly be explained
by the expression of other HLA-DR, -DQ and -DP molecules in
these individuals, contrasting to transgenic mice that carry only
one HLA class II allele. In the case of HLA-DR4-transgenic mice,
the fact that only 3 out of 7 recognized epitopes matched human
responses is probably due to the fact that only a single HLA-DR4
HIV-1 infected patient was tested [32] (Table S3). Our finding
that HLA class II transgenic strains could recognize up to 11
CD4+ T cell epitopes further indicates the ability of HIVBr18 to
induce broad responses in the context of multiple HLA class II
molecules. Considering that each HLA class II-transgenic strain
only expresses one, rather than the 3–8 distinct class II specificities
found in different HLA-DR,-DQ, and -DP haplotypes carried by
humans; and the inefficient binding of HLA class II molecules with
the murine CD4 molecule [46], our results indicate that the breath
and magnitude of the CD4+ T cell response to the HIVBr18
immunogen may be even higher in humans. We observed that
approximately 80% of mice from HLA-DR2, -DR4 and -DQ6
transgenic strains responded to the vaccination regimen, while
Figure 2. Immunization with HIVBr18 induces responses in
human HLA- class II transgenic mice. Splenocytes derived from -
DR2, -DR4, -DQ6 and -DQ8 transgenic mice immunized with HIVBr18 or
the pVAX1 vector alone were cultured with pooled HIV-1 peptides.
Proliferation of CFSE- labeled CD3
+CD4+ (A) and CD3
+ CD8
+ (B) T cells
from transgenic mice. The stimulation index was calculated by the fold
increase between stimulated versus unstimulated cell cultures. (C) IFN-c
production by T cells from HIVBr18- (black bars) or pVAX1- (white bars)
immunized mice. HLA class II-transgenic mouse strains are indicated in
X axis.
doi:10.1371/journal.pone.0011072.g002
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response (data not shown). This may be due to qualitatively
different levels of HLA class II expression. Regarding CD8+ T cell
recognition of murine MHC class I-restricted peptides, it should
be noticed that each HLA class II transgenic strain was
backcrossed to mouse strains with distinct H-2 class I backgrounds
[47], [48], [49].Our data confirmed the ability of the HIVBr18
immunization strategy in inducing broad HIV-1-specific prolifer-
ative and cytokine T cell responses in all HLA-DR and -DQ
transgenic strains of mice tested. We observed T cell recognition of
16 out of the 18 epitopes encoded by the vaccine, thus showing
that nearly all epitopes in HIVBr18 were adequately processed
and presented. This implies that, on average, each strain of mice
recognized epitopes corresponding to ca. 50% of the length of the
insert encoded by HIVBr18. This is higher than the epitope
coverage from conventional whole gene/protein HIV-1 vaccines.
Although we used a CD4+ epitope-based DNA vaccine, we could
also detect CD8+ T cell responses. This is not unexpected, since
78% of HIV-1 infected patients displayed CD8+ T cell responses
to the pooled HIV-1 peptides, usually coexisting with CD4+ T cell
responses [32]. Furthermore, 9 out of the 18 peptides contain
known human or murine MHC class I-restricted CD8 epitopes
[50]. To our knowledge, this is the first report of using multiple
HLA class II transgenic strains of mice as a model to probe
immunogenicity and HLA class II-restricted T cell responses
elicited by a vaccine against an infectious disease. Data suggest
that immunization with HIVBr18 might provide significant
coverage of the genetically heterogeneous human population.
The significant HIV-1- specific proliferative CD4+ T cell
responses in immunized mice was indicative of the magnitude of
the T helper activity elicited by HIVBr18. In spite of the abundant
evidence that cytotoxic CD8+ T lymphocytes (CTL) are the
primary anti-HIV-1 effectors [16], a significant amount of
information supports a protective role of specific CD4+ responses
in HIV-1/SIV and other viral infections. Early HIV-1 specific
CD4
+ T cell responses were associated with slower progression in
HIV-1 infection [19], [20]. Elite controller SIV-infected macaques
mount broad CD4+-specific T cell responses, and certain macaque Table 1. Immunization with HIVBr18 induces CD4+ T cell
proliferation in human HLA- class II transgenic mice.
Stimulus DR2 DR4 DQ6 DQ8
p17(73–89) 0.86 1.72
p24(33–45)
p24 (131–150)
p6(32–46) 1.57
pol (63–77) 0.40 1.64
pol (136–150) 0.13 3.27
pol (785–799) 2.54
gp41(261–276)
gp160(19–31) 0.35 1.42
gp160(174–185) 1.35
gp160(188–201) 0.31 4.33
gp160(481–498)
rev (11–27) 1.42
vpr (58–72)
vpr (65–82)
vif (144–158) 3.24
vpu (6–20)
nef (180–194) 14.17 2.00 1.46
cutoff 6.89 0.10 1.21 2.40
recognized peptides 1 6 11 0
Quantitative analysis of proliferating CD4
+ T cells (gated on CD3
+CD4
+ CFSE
low
cells) from HIVBr18 immunized transgenic mice. Proliferative responses
measured 15 days after immunization. Only proliferative (%CFSE
low) responses
above cutoff are shown. Cutoff values for each transgenic strain are shown in
the table. % CFSE
low cell values were calculated after subtraction of % CFSE
low
cells in unstimulated cultures. Since we observed different background values
in the CFSE assay among each mouse strain, individual cutoffs were established
to distinguish the random noise from the true proliferation values. The
nonspecific proliferative response was found to be from 0.10% to 6.89%.
doi:10.1371/journal.pone.0011072.t001
Table 2. Immunization with HIVBr18 induces CD8+ T cell
proliferation in human HLA- class II transgenic mice.
Stimulus DR2 DR4 DQ6 DQ8
p17(73–89)
p24(33–45) 0.87
p24 (131–150)
p6(32–46)
pol (63–77)
pol (136–150) 7.94 6.94
pol (785–799) 8.82
gp41(261–276) 2.4
gp160(19–31) 8.33
gp160(174–185) 12.42
gp160(188–201)
gp160(481–498)
rev (11–27)
vpr (58–72)
vpr (65–82)
vif (144–158)
vpu (6–20)
nef (180–194)
cutoff 7.29 0.01 12.60 0.59
recognized peptides 4 2 0 1
Quantitative analysis of proliferating CD8
+ T cells (gated on CD3
+CD8
+ CFSE
low
cells) from HIVBr18 immunized transgenic mice. Proliferative responses
measured 15 days after immunization. Only proliferative (%CFSE
low) responses
above cutoff are shown. Cutoff values for each transgenic strain are shown in
the table. For cutoff value calculation, see Table 1. The nonspecific proliferative
response was found to be from 0.01% to 12.60%.
doi:10.1371/journal.pone.0011072.t002
Figure 3. Immunization with HIVBr18 induces IFN-c secretion against multiple epitopes in human HLA class II transgenic mice. Two
weeks after the last immunization with HIVBr18 or the empty pVAX1 vector, splenocytes derived from individual HLA-DR2 (A), -DR4 (B), -DQ6 (C) and -
DQ8 (D) transgenic mice (6 per group) were cultured with individual HIV-1 peptides overnight. IFN-c production was measured by ELISPOT assay. HIV
peptide-specific cellular immune responses from human HLA class II- transgenic mice that responded to the immunization are displayed. SFU, spot-
forming units. Cutoff=10 SFU/10
6 cells and is represented by the dotted line. (SFU from pVAX1-immunized group were always below 5 SFU/10
6 cells).
doi:10.1371/journal.pone.0011072.g003
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[51]. Vaccination with the attenuated virus SIVmac239DNef [52]
or an 8-valent SIV Adenovirus 5 vaccine [5] both induce broad,
high frequency CD4+T cell responses and protect against
pathogenic SIV challenge. Significantly, CD4+ T cell depletion
in Rhesus macaques reduced the vaccine-induced protective effect
against SIV challenge [53]. Some vaccine approaches have been
especially designed to induce HIV-specific CD4+ T cells. An anti-
DEC205-HIV-1 gag fusion mAb induced a CD4+ T cell response
which conferred protection against challenge with recombinant
vaccinia-HIV-1 gag [54]. It follows that novel immunization
strategies should also aim to elicit strong CD4+ as well as CD8+ T
cell responses, in order to confer long-term protective immunity
[55].
We hereby demonstrate that immunization with HIVBr18, a
DNA plasmid encoding a string of conserved multiple HLA class
II-binding HIV-1 CD4+ T cell epitopes, can induce IFN-c
secretion, CD4+ and even some CD8+ T cell proliferation against
multiple epitopes. Moreover, this T cell response was multiallelic,
being able to elicit responses restricted to several distinct HLA
class II molecules. Previous data from our group has shown that
common HLA-DR molecules bind to multiple peptides encoded in
the vaccine [32]. This indicates that T cells from individuals
bearing such HLA molecules could potentially develop broad
immune responses to vaccination with the conserved epitopes of
HIVBr18. Thus, this vaccine concept may cope with HIV genetic
variability by increasing breadth, as well as providing increased
population coverage. We believe this insert design may be useful as
a source of cognate T cell help in novel HIV-1 vaccine candidates.
Materials and Methods
Construction of DNA plasmid encoding multiple HIV-1
epitopes
We designed a multiepitopic construct containing the nucleotide
sequence encoding the 18 HIV-1 epitopes described by Fonseca
et al. (2006): [32] p17(73–89), p24 (33–45), p24 (131–150), p6 (32–
46), protease (7–21), protease (80–94), integrase (70–84),
gp41(261–276), gp160 (19–31), gp160 (174–185), gp160 (188–
201), gp160 (481–498), rev (11–27), vpr (58–72), vpr (65–82), vif
(144–158), vpu (6–20), nef (180–194). Epitope sequences, assem-
bled in tandem in the above mentioned order, had GPGPG spacers
at C and N termini, to avoid the creation of junctional epitopes
and interference with processing and presentation [56]. The
sequences of such epitopes are available in Supplementary Table
S1. The nucleotide sequence was codon-optimized and a Kozak
sequence was included at the 59 end to improve mammalian
expression. The synthetic gene was built (EZBiolab, USA, http://
www.ezbiolab.com) and subcloned using HindIII and XhoI sites of
the expression vector pVAX-1 (Invitrogen) for production of the
recombinant DNA plasmid HIVBr18. The presence and correct
orientation of the gene encoding the selected epitopes was
confirmed by direct sequencing using the T7 oligonucleotide.
Large-scale preparations of plasmid DNA’s HIVBr18 and the
empty vector pVAX1 were prepared with the EndofreeH Giga
Plasmid Purification Kit from Qiagen according to manufacturer’s
instructions. The yield and quality of purified DNA was
determined by spectrophotometry at 260 nm and confirmed by
agarose gel electrophoresis with ethidium bromide staining.
Mice and Immunizations
Six to eight week-old female HLA-class II transgenic mice.
DRB1* 1502 (DR2), DRB1*0401 (DR4), DQB1* 0601(DQ6) and
DQB1*0302 (DQ8) were used in this study [47], [48], [49]. All
transgenic mice were kindly provided by Dr. Chella S. David
(Department of Immunology, Mayo Clinic, Rochester). Mice used
for transgene expression were made genetically deficient for the
endogenous class II genes (I-A
0,E
0) by homologous recombina-
tion. The expression of human HLA class II molecules on antigen-
presenting cells in the thymus and periphery of these transgenic
mice has a similar distribution to that of endogenous mouse MHC
class II molecules [46]. Mice were kept and manipulated in SPF
conditions in the animal care facilities of the Institute of Tropical
Medicine, University of Sa ˜o Paulo (IMT/FMUSP). Experiments
were performed in accordance to the guidelines of the Ethical
committee of University of Sa ˜o Paulo. Six mice per group were
injected with 10 mM cardiotoxin (Sigma) five days before
vaccination. At weeks 0, 2 and 4, DNA plasmid HIVBr18 or
empty vector pVAX1 was administered intramuscularly. Each
quadriceps was injected with 50 ml of DNA at a concentration of
Figure 4. Number of recognized epitopes by spleen cells from HIVBr18 immunized HLA-DR2, -DR4, -DQ6 and -DQ8 transgenic mice.
Overall peptide-specific responses observed with IFN-c ELISPOT, CD4+ and CD8+ T cell proliferation assays in each HLA-transgenic mouse strain are
depicted.
doi:10.1371/journal.pone.0011072.g004
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of plasmid DNA. Two weeks after the last DNA injection, mice
were euthanized with CO2.
Peptides
The eighteen multiple HLA-DR binding, frequently recognized
peptides, derived from the conserved regions of HIV-1 B-subtype
consensus and selected from the whole proteome [32] (sequences
in Supplementary Table S1) were synthesized in house by solid
phase technology. The 9-fluorenylmethoxycarbonyl (Fmoc) strat-
egy, with the C- terminal carboxyl group in amide form, was used
for synthesis [57]. Peptide purity and quality were assessed by
reverse-phase high performance liquid chromatography and mass
spectrometry and was routinely above 90%.
Spleen cell isolation for immune assays
Two weeksafterthelastimmunization, micewereeuthanized and
spleens were removed aseptically. After obtaining single cell
suspensions, cells were washed in 10 ml of RPMI 1640. Cells were
then ressuspended in R-10 (RPMI supplemented with 10% of fetal
bovine serum (GIBCO), 2 mM L-glutamine (Sigma), 10 mM Hepes
(Sigma), 1 mM sodium piruvate, 1% vol/vol non-essential aminoa-
cid solution, 40 mg/ml of Gentamicin, 20 mg/ml of Peflacin and
5610
25 M 2- mercaptoetanol (SIGMA). The viability of the cells
was evaluated using 0.2% Trypan Blue exclusion dye to discriminate
between live and dead cells. Cell concentration was estimated with
the aid of a Neubauer chamber and adjusted in cell culture medium.
IFNc ELISPOT assays
Splenocytes from HIVBr18 or pVAX1 immunized mice were
assayed for their ability to secrete IFN- c after in vitro stimulation
with 5 mM of individual or pooled HIV-1 peptides using an
ELISPOT assay. The ELISPOT assay was performed using Becton
Dickinson murine IFN-c ELISPOTkit accordingto manufacturer’s
instructions. Spots were counted using an automated stereomicro-
scope (KS ELISPOT, Zeiss, Oberkochem, Germany). The number
of antigen specific T cells, expressed as IFN-c spot-forming units
(SFU)/10
6 splenocytes was calculated after subtracting negative
control values (wells with cells in the absence of peptide). The
positivity cutoff was calculated as the mean 63 SD of splenocytes
from pVAX1 immunized mice, stimulated with all peptides. The
cutoff for IFN-c was 10 SFU/10
6 splenocytes.
CFSE-based proliferation assay
Splenocytes from HIVBr18 or pVAX1-immunized mice were
assayed for their ability to proliferate in vitro after stimulation with
HIV-1 peptides using the CFSE dilution based proliferation assay
[58]. Freshly isolated splenocytes from immunized mice were
resuspended (50610
6/ml) in PBS, labeled with 1.25 mM of CFSE
at 37uC for 10 minutes. The reaction was quenched with RPMI
1640 supplemented with 10% FBS and cells were washed before
resuspending in RPMI 1640 at a density of 1.5610
6/ml. Cells
were cultured in 96-well-round-bottomed plates (3610
5/well in
triplicate) for 5 days at 37uC and 5%CO2 with medium alone or
5 mM of HIV peptides. Positive controls were stimulated with
2.5 mg/mL of Concanavalin A (Sigma). Cells were then harvested,
washed with 100 mL of FACS buffer (PBS with 0.5% BSA and
2 mM EDTA) and stained with anti-mouse CD3 phycoerythrin
(PE), anti-mouse CD4 peridinin chlorophyll protein (PerCP) and
anti-mouse CD8 allophycocyanin (APC) (BD Pharmingen, San
Jose, CA) for 45 minutes at 4uC. Cells were then washed twice
with FACS buffer, fixed with 4% paraformaldehyde, and
resuspended in FACS buffer. Samples were acquired on a
FACSCanto flow cytometer (BD Biosciences) and then analyzed
using FlowJo software (version 8.7.1, Tree Star, San Carlo, CA).
Fifty thousand events (proliferation evaluation) were acquired in a
live lymphocyte gate. The percent of proliferating CD4 + and
CD8 +T cells, i.e., CFSE-low cells, was determined in the CD3 +
cell population. The criteria for scoring as positive the proliferating
cell cultures included CFSE-low cells . cut off. The cutoff of
unspecific proliferative response was determined based on the
median percentage of proliferating cells (% of CD3+CD4+ or
CD3+CD8+ CFSE low cells) on splenocytes from pVAX-
immunized groups after stimulating with individual peptides +3
standard deviations; or stimulation index .2: the stimulation
index was calculated by the following equation: %CFSE
low cells
after stimulus/%CFSE
low unstimulated cell cultures.
Data Analysis
Statistical significance (p-values) was calculated by using a
Student’s T test or One-way ANOVA and Tukey’s honestly
significantly different (HSD). Statistical analysis was performed
with GraphPad Prism version 4.0 software.
Supporting Information
Table S1 Peptide sequences derived from conserved regions of
B-subtype HIV-1 consensus selected for multiple HLA-DR
binding by the TEPITOPE algorithm and recognition by PBMC
from HIV-1-infected patients.
Found at: doi:10.1371/journal.pone.0011072.s001 (0.04 MB
DOC)
Table S2 Epitope recognition by HLA-DR2 transgenic mice
and HIV-1-infected patients bearing the same haplotype.
Found at: doi:10.1371/journal.pone.0011072.s002 (0.06 MB
DOC)
Table S3 Epitope recognition by HLA-DR4 transgenic mice
and HIV-1-infected patient bearing the same haplotype.
Found at: doi:10.1371/journal.pone.0011072.s003 (0.04 MB
DOC)
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